News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
Curatis Holding AG receives positive outcome confirmation from FDA meeting regarding corticorelin's Phase 3 development plan for patients with PTBE secondary to solid tumor brain metastases -
-
-
COMMUNIQUÉ DE PRESSE
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01
Curatis Holding AG reports double-digit revenue growth in H1 2025, signing a significant partnership with Phoenix Labs for C-PTBE-01. Financials show a loss due to increased development expenses for corticorelin -